Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETIP for Tobacco Cessation in HNSCC and NSCLC
NCT04694846Completed
- Sponsor
- Thomas Jefferson University
- Start
- Aug 2020
- Primary completion
- Aug 2024
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nicotine patch, bupropion and varenicline in Tobacco Use Disorder (TUD) (2 arms), sponsored by Thomas Jefferson University. Primary endpoint: Reduction in daily number of cigarettes smoked at 6 months. Started Aug 2020; status: completed.
02
Drugs
nicotine patchbupropionvarenicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04694846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04694846.